Definium Therapeutics (NASDAQ:DFTX) Releases Quarterly Earnings Results, Misses Estimates By $0.89 EPS

Definium Therapeutics (NASDAQ:DFTX) announced its earnings results on Thursday. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89), FiscalAI reports.

Here are the key takeaways from Definium Therapeutics’ conference call:

• EMERGE phase III results were highly positive, with DT120 ODT producing an 8.1-point placebo-adjusted MADRS improvement in major depressive disorder at week six, statistically significant benefits from week one through week 12, and what management described as a favorable tolerability profile.
• Definium expects to report topline results from its VOYAGE phase III generalized anxiety disorder study during the week of August 10, 2026, followed by PANORAMA results in September; both trials completed enrollment and were estimated to have more than 99% power to detect the targeted treatment effect.
• The company raised approximately $758 million in net proceeds from an upsized public offering and ended the quarter with about $1.1 billion in cash, cash equivalents, and investments, which management believes can fund operations into 2030.
• Definium is expanding its commercial infrastructure ahead of a potential DT120 launch, including market access, sales, patient support, payer engagement, and clinician-awareness initiatives for GAD and MDD.
• Quarterly net loss increased to $159 million from $42.7 million a year earlier, while R&D and G&A expenses rose substantially as the company invested in clinical programs, personnel, and commercialization; an $86.2 million non-cash warrant valuation expense was a major contributor to the loss.

Definium Therapeutics Stock Up 6.9%

Definium Therapeutics stock traded up $3.19 on Friday, hitting $49.33. 418,078 shares of the stock traded hands, compared to its average volume of 2,243,467. Definium Therapeutics has a 1 year low of $8.70 and a 1 year high of $49.70. The firm has a market cap of $4.92 billion, a P/E ratio of -19.81 and a beta of 2.23. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15. The business’s fifty day simple moving average is $37.45 and its 200 day simple moving average is $25.72.

Wall Street Analyst Weigh In

DFTX has been the topic of a number of research analyst reports. Oppenheimer set a $60.00 price objective on shares of Definium Therapeutics and gave the company an “outperform” rating in a research report on Monday, June 22nd. Citigroup reaffirmed a “buy” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Friday, July 17th. Needham & Company LLC upped their target price on Definium Therapeutics from $38.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, June 23rd. Finally, Leerink Partners set a $52.00 price objective on shares of Definium Therapeutics and gave the stock an “outperform” rating in a report on Monday, June 22nd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Definium Therapeutics has a consensus rating of “Buy” and a consensus price target of $54.85.

Insider Buying and Selling at Definium Therapeutics

In related news, insider Matthew T. Wiley sold 2,867 shares of Definium Therapeutics stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $129,101.01. Following the completion of the transaction, the insider directly owned 174,633 shares of the company’s stock, valued at $7,863,723.99. This trade represents a 1.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Mark Sullivan sold 13,008 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $585,750.24. Following the transaction, the insider directly owned 320,571 shares of the company’s stock, valued at $14,435,312.13. This represents a 3.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 48,096 shares of company stock valued at $2,165,763 in the last quarter. 2.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Definium Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Scientech Research LLC purchased a new position in Definium Therapeutics in the third quarter worth about $286,000. Mercer Global Advisors Inc. ADV grew its holdings in shares of Definium Therapeutics by 10.5% during the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after buying an additional 2,079 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Definium Therapeutics during the third quarter valued at approximately $379,000. BNP Paribas Financial Markets raised its holdings in Definium Therapeutics by 82.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,320 shares of the company’s stock worth $181,000 after acquiring an additional 6,903 shares during the last quarter. Finally, Blair William & Co. IL lifted its position in Definium Therapeutics by 43.6% in the 3rd quarter. Blair William & Co. IL now owns 31,905 shares of the company’s stock valued at $376,000 after acquiring an additional 9,687 shares in the last quarter. 27.91% of the stock is owned by institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.